[Alpha Biz= Reporter Kim Sangjin] HanDok announced on the 24th that it has entered into an exclusive distribution agreement with Biocon, a global biopharmaceutical company, for the obesity treatment medication containing the active ingredient Liraglutide in the domestic market.
The obesity treatment medication developed by Biocon contains the active ingredient Liraglutide, which is a glucagon-like peptide-1 (GLP-1) analog synthesized based on peptide synthesis technology, aimed at lowering blood sugar levels in diabetic patients or reducing body weight in obese patients.
Through this agreement, HanDok will be responsible for obtaining domestic product approval and handling sales and distribution of the obesity treatment medication containing Liraglutide.
AlphaBIZ Kim SangJin(letyou@alphabiz.co.kr)
